Notwithstanding encouraging clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from PBMs. Such insurers are typically creating obstacles to access, such as high cost restrictions and approval processes that limit consumer access. Market believe that thes… Read More